IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of "Moderate Buy" by Analysts

Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the thirteen ratings firms that are presently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $47.55.

Several research firms have recently issued reports on IDYA. Royal Bank Of Canada raised shares of IDEAYA Biosciences from an "outperform" rating to a "moderate buy" rating and lowered their target price for the stock from $57.00 to $30.00 in a research note on Wednesday, July 9th. Wells Fargo & Company initiated coverage on shares of IDEAYA Biosciences in a research note on Thursday, June 26th. They issued an "overweight" rating and a $44.00 price target for the company. The Goldman Sachs Group raised shares of IDEAYA Biosciences to a "hold" rating and set a $25.00 price target for the company in a research note on Thursday. Finally, JPMorgan Chase & Co. increased their price target on shares of IDEAYA Biosciences from $63.00 to $66.00 and gave the company an "overweight" rating in a research note on Thursday, May 22nd.

Institutional Trading of IDEAYA Biosciences

A number of institutional investors have recently added to or reduced their stakes in the stock. CWM LLC raised its stake in IDEAYA Biosciences by 325.7% during the first quarter. CWM LLC now owns 2,371 shares of the company's stock worth $39,000 after purchasing an additional 1,814 shares during the period. PNC Financial Services Group Inc. raised its stake in shares of IDEAYA Biosciences by 180.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company's stock valued at $39,000 after acquiring an additional 1,546 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of IDEAYA Biosciences in the 4th quarter valued at $47,000. Signaturefd LLC raised its stake in shares of IDEAYA Biosciences by 374.8% in the 1st quarter. Signaturefd LLC now owns 2,877 shares of the company's stock valued at $47,000 after acquiring an additional 2,271 shares during the period. Finally, Parallel Advisors LLC raised its stake in shares of IDEAYA Biosciences by 72.4% in the 2nd quarter. Parallel Advisors LLC now owns 3,260 shares of the company's stock valued at $69,000 after acquiring an additional 1,369 shares during the period. Hedge funds and other institutional investors own 98.29% of the company's stock.

IDEAYA Biosciences Price Performance

NASDAQ:IDYA traded up $0.10 during mid-day trading on Friday, hitting $22.58. The company's stock had a trading volume of 743,184 shares, compared to its average volume of 1,167,036. IDEAYA Biosciences has a 1 year low of $13.45 and a 1 year high of $44.42. The stock has a market cap of $1.98 billion, a price-to-earnings ratio of -6.29 and a beta of 0.03. The business's fifty day moving average is $20.54 and its two-hundred day moving average is $20.44.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter in the prior year, the firm earned ($0.53) EPS. Analysts anticipate that IDEAYA Biosciences will post -3.07 EPS for the current fiscal year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.